Russell Investments Group Ltd. Sells 10,580 Shares of Moderna, Inc. $MRNA

Key Points

• Russell Investments Group Ltd. reduced its stake in Moderna, Inc. by 6.2%, selling 10,580 shares, and now holds 159,663 shares worth approximately $4.56 million.
• Several institutional investors have recently increased their holdings in Moderna, with notable increases from firms like Invesco Ltd. (17.5%) and The Manufacturers Life Insurance Company (8.7%).
• Moderna's latest earnings report showed a revenue of $142 million, surpassing analyst estimates, while it reported an EPS of ($2.13), beating expectations of ($2.99).

Russell Investments Group Ltd. reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 6.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,663 shares of the company's stock after selling 10,580 shares during the quarter. Russell Investments Group Ltd.'s holdings in Moderna were worth $4,557,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MRNA. Theleme Partners LLP lifted its stake in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock worth $303,819,000 after purchasing an additional 72,028 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after purchasing an additional 877,162 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Moderna by 8.7% during the 4th quarter. The Manufacturers Life Insurance Company now owns 3,341,924 shares of the company's stock valued at $138,957,000 after purchasing an additional 267,990 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Moderna by 13.6% during the 4th quarter. Northern Trust Corp now owns 2,959,054 shares of the company's stock valued at $123,037,000 after purchasing an additional 354,871 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock worth $74,557,000 after acquiring an additional 285,662 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. JPMorgan Chase & Co. set a $26.00 target price on shares of Moderna in a research report on Friday, August 1st. Bank of America dropped their target price on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Barclays dropped their target price on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a research report on Monday, August 4th. Finally, Royal Bank Of Canada dropped their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have issued a Hold rating and four have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Price Performance

NASDAQ MRNA traded down $0.63 during trading hours on Thursday, reaching $24.47. 10,557,153 shares of the company's stock traded hands, compared to its average volume of 9,630,788. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $79.96. The firm has a market cap of $9.52 billion, a PE ratio of -3.25 and a beta of 1.83. The firm has a 50-day simple moving average of $29.12 and a 200 day simple moving average of $28.89.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. During the same period last year, the company posted ($3.33) EPS. Moderna's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.